1.	A Study of Selumetinib in Patients With Kaposi's Sarcoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: STH16059, 2011-003099-35, NCT01752569
2.	Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01411, 10-053, CDR0000674866, N01CM00071, N01CM00100, N01CM00070, MSKCC-10053, 8443, NCT01143402
3.	AZD6244 and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01266, 10454, N01CM00070, R21CA149939, USCF-10454, 8598, NCT01222689
4.	Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 100218, 10-C-0218, NCT01229150
5.	BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2009-0360, P01 CA148133, NCT01248247
6.	Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02558, 12-0110, NU-10H03, CDR0000690641, N01CM00071, NCI-10H03, 8611, NCT01278615
7.	Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110096, 11-C-0096, NCT01306045
8.	MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110117, 11-C-0117, NCT01333475
9.	Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-00238, VICCMEL1120, N01CM00100, MCC-VICCMEL1120, 8867, NCT01519427
10.	Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Phase: Phase II Type: Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01993, S1115, CDR0000737878, SWOG-S1115, U10CA032102, NCT01658943
11.	Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00064, EudraCT number: 2012-003622-25, NCT01750281
12.	Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00065, EudraCT 2013-000423-14, NCT01843062
13.	Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 to 21 Sponsor: NCI Protocol IDs: NCI-2012-03173, PBTC-029, CDR667932, U01CA081457, NCT01089101
14.	MEK Inhibitor and Thoracic Radiotherapy Trial Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 09_DOG07_104, NCT01146756
15.	Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 09_DOG03_184, 2009-016524-31, NCT01160926
16.	Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 years and over Sponsor: NCI Protocol IDs: NCI-2012-02906, MC1012, U01CA069912, CDR0000700596, MAYO-MC1012, 8810, NCT01364051
17.	AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 to 18 Sponsor: NCI Protocol IDs: 110161, 11-C-0161, NCT01362803
18.	A Phase I Trial of Vandetanib (ZD6474) and Selumetinib (AZD6244)for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRUKD/11/001, NCT01586624
19.	Investigate the Safety and Tolerability of AZD6244 + Docetaxel in Japanese Patients With Non-Small Cell Lung Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00067, NCT01605916
20.	Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: Over 18 Sponsor: Other Protocol IDs: I215, NCT01783197
21.	Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00070, EudraCT number: 2012-005202-22, NCT01809210
22.	Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EPROST-20100252, NCT01313039